Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Braxia Scientific Corp C.BRAX

Alternate Symbol(s):  BRAXF

Braxia Scientific Corp. is a Canada-based medical research and telemedicine company with a clinic that provide ketamine treatments for persons with depression and related disorders. Through its medical solutions, it intends to reduce the illness burden of brain-based disorders, such as major depressive disorder, among others. The Company is primarily focused on owning and operating... see more

CSE:BRAX - Post Discussion

Braxia Scientific Corp > Braxia Patents Pending
View:
Post by newcoin on Aug 20, 2021 12:46pm

Braxia Patents Pending

Braxias Patents Pending

Last year Braxia acquired Tassili for clinical research. Tassili has a collaborative research agreement with the University of Miami’s Miller School of Medicine. The agreement covers dosing rats and mice who have been afflicted with a post-traumatic stress disorder or traumatic brain injury with PTSD a combination of psilocybin and CBD. The objective of the Tassili pre-clinical trials is to assess how the combination of psilocybin and CBD may mitigate the adverse effects of PTSD and a traumatic brain injury with PTSD.

Braxia also purchased the biotech company Altmed last year.

The transaction gave Braxia three trials in the Phase I stage and three trials in the preclinical stage during 2020, as well as seven patents for its ketamine/psilocybin delivery platforms and formulations.

Braxia acquired the biotech company Novo Formulations in March 2020 for IP development. Novo’s IP’s scope focuses on novel and innovative delivery systems for the pharmaceutical industry. Novo is actively formulating and developing bioavailable, delivery platforms, including topical creams, intranasal spray, and sublingual tabs.

Novo is also developing an intranasal formulation of racemic ketamine for the treatment of depression and pain. Chemical and analytic stability tests are being conducted at McMaster University. The project is set to be completed sometime later this year.

If they are the first to show ketamines successful use for a new disease (Suicide, TRD, PTSD or Bipolar D) in a Phase 3 Clinical Trial or sell it after Phase 2 to big pharma they get 3 year of exclusive rights by the FDA!

"A brand-name drug with an active ingredient that has been approved before may be awarded a three-year exclusivity in certain circumstances, such as if a new way of delivering the active ingredient is proposed (for example, a tablet rather than a liquid) or a different disease or condition the drug can treat is identified. To get this approval, the drug company must conduct new clinical studies in humans*."*

https://www.fda.gov/media/111069/download

posted on another board by PsyDelika
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities